Portal de Periódicos da CAPES

Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent

2017; SAGE Publishing; Volume: 36; Issue: 2 Linguagem: Inglês

10.1177/1091581817697685

1092-874X

Julia Parrish-Novak, Kelly Byrnes-Blake, Narine Lalayeva, Stefanie C.M. Burleson, Janean L. Fidel, Rhonda Gilmore, Pamela Gayheart‐Walsten, Gregory A. Bricker, William Crumb, Kirk Tarlo, Stacey Hansen, Valorie Wiss, Errol Malta, William S. Dernell, James M. Olson, Dennis M. Miller,

3D Printing in Biomedical Research

BLZ-100 is a single intravenous use, fluorescent imaging agent that labels tumor tissue to enable more complete and precise surgical resection. It is composed of a chlorotoxin peptide covalently bound to the near-infrared fluorophore indocyanine green. BLZ-100 is in clinical development for intraoperative visualization of human tumors. The nonclinical safety and pharmacokinetic (PK) profile of BLZ-100 was evaluated in mice, rats, canines, and nonhuman primates (NHP). Single bolus intravenous administration of BLZ-100 was well tolerated, and no adverse changes were observed in cardiovascular safety pharmacology, PK, and toxicology studies in rats and NHP. The single-dose no-observed-adverse-effect-levels (NOAELs) were 7 mg (28 mg/kg) in rats and 60 mg (20 mg/kg) in NHP, corresponding to peak concentration values of 89 400 and 436 000 ng/mL and area-under-the-curve exposure values of 130 000 and 1 240 000 h·ng/mL, respectively. Based on a human imaging dose of 3 mg, dose safety margins are >100 for rat and monkey. BLZ-100 produced hypersensitivity reactions in canine imaging studies (lethargy, pruritus, swollen muzzle, etc). The severity of the reactions was not dose related. In a follow-up study in dogs, plasma histamine concentrations were increased 5 to 60 minutes after BLZ-100 injection; this coincided with signs of hypersensitivity, supporting the conclusion that the reactions were histamine based. Hypersensitivity reactions were not observed in other species or in BLZ-100 human clinical studies conducted to date. The combined imaging, safety pharmacology, PK, and toxicology studies contributed to an extensive initial nonclinical profile for BLZ-100, supporting first-in-human clinical trials.